CClinicalTrials.gg
CompletedNCT07687641ozone-ımplantUpdated Sep 16, 2026

CBCT Assessment of Marginal Bone Changes With Ozone Therapy

An interventional study of Gaseous Ozone Application and Conventional Implant Placement in Peri-Implant Marginal Bone Loss and Dental Implantation, sponsored by Adiyaman University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Adiyaman University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Sep 2025, registered Jun 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study examined whether adding local gaseous ozone to standard dental implant treatment could reduce early bone loss around implants. Fifty adults requiring matched implants on opposite sides of the same jaw participated. Within each participant, matched implant sites were randomly assigned to ozone treatment or standard treatment without ozone. Ozone was applied to the prepared implant socket during surgery and to the peri-implant surgical site after suturing and on postoperative days 1, 3, 5, and 7. Changes in marginal bone levels from baseline to 6 months were assessed using cone-beam computed tomography (CBCT).

Read the detailed description

This prospective, split-mouth randomized clinical trial was conducted at the Department of Periodontology, Faculty of Dentistry, Adıyaman University. Participants required implant placement at matched contralateral posterior sites within the same jaw. Within each participant, matched implant sites were randomly allocated to adjunctive local gaseous ozone treatment or standard treatment without ozone. Ozone was applied to the prepared implant socket during surgery and to the peri-implant surgical site after suturing and on postoperative days 1, 3, 5, and 7. Fifty participants were enrolled; two were lost to follow-up, and 48 participants with 152 implants completed the study. The final analysis included 76 ozone-treated and 76 control implants. The primary outcome was the change in peri-implant marginal bone level from baseline to 6 months, assessed using cone-beam computed tomography at the buccal, palatal/lingual, mesial, and distal implant surfaces. The outcome assessor was blinded to treatment allocation.

02

Conditions studied

  • Peri-Implant Marginal Bone Loss
  • Dental Implantation

Browse trials for

Keywords

  • Ozone
  • Dental Implant
  • Cone-Beam Computed Tomography
  • Alveolar Bone Loss
03

In context

Alveolar Bone Loss

297 studies on the registry are indexed under Alveolar Bone Loss; 76 are open to participants now.

This study's enrollment of 50 is above the median of 25 across 254 interventional studies indexed under Alveolar Bone Loss.

Browse Alveolar Bone Loss studies →

Lead sponsor

Adiyaman University is the lead sponsor of 28 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Adults aged 18 to 65 years.
  • Systemically healthy individuals.
  • Ability to comply with the study procedures and follow-up visits.
  • Requirement for implant placement at matched contralateral posterior sites within the same jaw.
  • Healed edentulous sites suitable for conventional implant placement.
  • Adequate alveolar bone volume for placement of implants measuring 3.5-4.0 mm in diameter and 8-12 mm in length without the need for advanced bone augmentation, with at least 1.5 mm of surrounding bone.
  • Initial soft-tissue thickness of at least 2 mm and keratinized mucosal width of at least 2 mm at the implant sites.
  • Provision of written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Systemic diseases or medical conditions contraindicating implant surgery.
  • Pregnancy.
  • Smoking.
  • Active oral infection or advanced periodontal disease.
  • Insufficient bone volume requiring advanced bone augmentation.
  • Incomplete healing at the intended implant site following recent tooth extraction.
  • Previous implant failure at the intended implant site.
  • Any contraindication to ozone therapy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Gaseous Ozone Application

    Within each participant, one or more matched implant sites were randomly allocated to adjunctive local gaseous ozone treatment. Ozone was applied to the surgically prepared implant socket before implant placement and to the peri-implant surgical site after suturing and on postoperative days 1, 3, 5, and 7. All sites also received standard surgical and postoperative care.

    Procedure: Gaseous Ozone Application

  • Active comparator
    Conventional Implant Placement

    Within each participant, the corresponding contralateral matched implant site or sites were allocated to the control treatment. These sites received conventional implant placement and standard postoperative care without ozone application at any time point.

    Procedure: Conventional Implant Placement

Interventions

  • ProcedureGaseous Ozone Application

    Gaseous ozone was applied to the surgically prepared implant socket before implant placement. Following suturing, ozone was applied locally to the peri-implant surgical site and was repeated on postoperative days 1, 3, 5, and 7.

  • ProcedureConventional Implant Placement

    Implants were placed using the standard surgical protocol, followed by standard postoperative care, without intraoperative or postoperative ozone application.

06

What researchers measure

Primary outcomes

  1. Change in Marginal Bone Level Around Dental Implants

    Using cone-beam computed tomography (CBCT), the vertical distance from the implant shoulder to the first bone-to-implant contact was measured in millimeters at the buccal, palatal/lingual, mesial, and distal surfaces at baseline and 6 months. For each surface, marginal bone level change was calculated as the 6-month distance minus the baseline distance; positive values indicated greater marginal bone loss. Combined buccolingual and mesiodistal measurements were calculated by averaging the corresponding surface measurements. Changes were compared between matched ozone-treated and control implant sites.

    Time frame: Baseline and 6 months after implant placement

07

Study locations

1 site
  • Faculty of Dentistry, Adıyaman University
    Adıyaman, Merkez 02030, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because the informed consent obtained from participants did not include external sharing of individual-level data. Aggregated study findings will be reported in the publication.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07687641
Lead sponsor
Adiyaman University
Responsible party
Zeliha Başak Çakır Erdil (Research Assistant in Periodontology, Adiyaman University) — Principal investigator
First posted
Jul 7, 2026
Start date
Sep 3, 2025
Primary completion
May 18, 2026
Completion
May 18, 2026
Last update
Sep 16, 2026

Study contacts

METİN ÇALIŞIR, PhD
principal investigator · Department of Periodontology, Faculty of Dentistry, Adıyaman University, Adıyaman, Turkey

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion